KCAS Bio will be attending the 27th North American Meeting of the International Society for the Study of Xenobiotics (ISSX), taking place October 11-14, 2026, in San Francisco, California.
The 2026 meeting, themed “Back to the Future: DMPK Foundations and New Concepts,” will bring together scientists and researchers to explore the evolving science of drug metabolism and pharmacokinetics. The scientific program spans foundational DMPK principles and emerging approaches across ADME, biotransformation, drug-drug interactions, mechanistic modeling, and new drug modalities.
The 27th North American ISSX Meeting provides an opportunity to connect with researchers advancing DMPK and ADME science and discuss the bioanalytical challenges shaping drug discovery and development.
Bioanalytical Expertise for Evolving DMPK Challenges
As drug modalities become increasingly complex, understanding exposure, metabolism, biotransformation, and pharmacokinetics requires bioanalytical strategies that can adapt to the molecule and the questions being asked.
KCAS Bio supports drug development programs across small molecules, biologics, antibodies, ADCs, oligonucleotides, and other complex modalities. Our capabilities include LC-MS/MS, hybrid LC-MS/MS, ligand binding assays, molecular assays, and other specialized bioanalytical approaches.
Connect with Our Team
David Good will be attending the 27th North American ISSX Meeting. Connect with our team to discuss the bioanalytical considerations behind your DMPK, ADME, PK, biotransformation, or complex modality program.
Whether you are working with a small molecule, biologic, therapeutic antibody, ADC, oligonucleotide, or another complex modality, we welcome the opportunity to discuss how KCAS Bio can support your bioanalytical needs.
We look forward to connecting in San Francisco.